$2195 | Single User
$7725 | Site License
$14950 | Global License

Drug Delivery - Innovations, trends, and their impact on pharma

Published by FirstWord Pharma: 01 Nov 2015 | 271 | In Stock

Introduction

Introduction


Why you need Drug Delivery - Innovations, trends, and their impact on pharma


Revolutionary changes are disrupting the status quo simply through developments in the way drugs are given to patients. In a rapidly evolving field, drug delivery systems are offering growth opportunities and solutions – as well as presenting difficulties – as the range of choices grows.


To make sure you don't get left behind you need to understand what is happening at the cutting edge from experts innovating and leading the way through the technological and regulatory minefield. See how companies like Sanofi, Surefire Medical and Invion among other market leaders explain how they see the market and how they are dealing with the challenges.


Puchase Reasons


Top Takeaways:


  • Change is accelerating. There's a wide range of new products at late-stage development, 200+ partnership deals are signed each year and device companies are now entering the market directly

  • Reliance on delivery mechanisms is increasing as health economics requirements on efficacy and cost-effectiveness multiply

  • Significant delivery mechanism opportunities still exist with the potential to solve unmet needs with new formulations

  • Drug combinations offer risks and rewards – the promise of innovative formulas is potentially hampered by technology and regulation

  • Product franchises are protected by differentiating products and by extending a profitable drug's lifecycle

  • Opportunities are growing in new markets as the Far East opens up and China expands healthcare to the wider population

  • Key Issues Explored


  • Key drivers and how devices are transforming the market including oral medicines, inhalers, injectable devices, patches, subdermal implants, neurostimulation and smart devices

  • The challenges faced in choosing and developing the right delivery system and formulations, looking at biopharmaceuticals, biologics, excipients, large and small molecules, peptides, proteins and biosimilars

  • Hurdles to commercialisation globally – how companies are evolving strategies to deal with local regulatory issues for global products

  • Improving patient compliance with better outcomes and the potential for home-based care offered by some systems

  • The value of overcoming technical challenges before clinical trials begin

  • The cost-benefit considerations of different development models including outsourcing, partnerships and internal development.

  • The impact of health economics on innovation in the drug delivery market, reimbursement concerns and access issues

  • Who needs this report?


  • Presidents and VPs of product development – to see the drugs and devices in the pipeline and the potential opportunities and risks involved

  • Business development directors – to get support and improve and refine strategic direction and decisions

  • Device development team managers – to see expansion possibilities and the current state of the competitive market

  • Delivery and formulation specialists – to analyse current best practice

  • Manufacturers of devices – to see the top drug delivery partnerships and get an overview of growth prospects

  • Insurers and payers – to gain insights into the value of more effective delivery mechanisms to ensure the best use of limited resources

  • Big data companies and electronic health companies – to see current and future developments in connected devices

  • Contributors


  • Director, Drug Delivery Technologies, European Pharma Company,

  • Vice President, Medical Device Development, Global pharma Company

  • Igor Gonda: President & CEO, Aradigm Corporation [Linkedin]

  • Jeff Macdonald: Senior Director, Corporate Communications, Acorda Therapeutics

  • Seth Yakatan: CSO, Vice President of Business Development, Invion Group

  • Director, Corporate Development, Respiratory Product Development Company

  • Director, Pharmaceutical Sciences, Respiratory Product Development Company Douglas Marenzi: CEO, PHC Technologies

  • David Urquhart: Business Development, PHC Technologies

  • Morten Nielsen: CEO, Medicom Innovation Partner

  • Frédéric Gabriel: CSO and General Manager, Haselmeier

  • Jim Chomas Ph.D: President and CEO, Surefire Medical

  • Norman Weldon: Chairman, SureFire Medical

  • Julian Chick, Ph.D: COO, Admedus Ltd

  • JP Errico, Ph.D: CEO, electroCore Medical

  • About FirstWord


    FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


    FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.


    FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

    Table of Contents
    for Drug Delivery - Innovations, trends, and their impact on pharma

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    271 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Orphan Drug Commercialisation and Market Access in Emerging Markets
    IntroductionMarket access for orphan drugs: Can your company break through in emerging markets?Find ...
    01 Jul 2016 by FirstWord Pharma USD $695 More Info
    Orphan Drug Commercial Models: Sustaining the rare disease business
    IntroductionChoosing the right commercial model for orphan drug successThe societal and commercial a...
    01 May 2016 by FirstWord Pharma USD $695 More Info
    Pay-for-Performance and Drug Pricing: Impact and Response of Pharma [2016]
    IntroductionThe pay for performance agenda gathers pace as US payers rebel the cost of drugs.Pharma ...
    01 Mar 2016 by FirstWord Pharma USD $695 More Info
    Innovations in Drug Pricing and Reimbursement (2016)
    IntroductionIs the drug pricing bubble about to burst?Drug costs are becoming unaffordable and draco...
    01 Feb 2016 by FirstWord Pharma USD $2,195 More Info
    Physician Views: Which companies excel in diabetes drug marketing and why?
    Scope With both the insulin and non-insulin segments of the diabetes market expected to become more ...
    01 May 2015 by FirstWord Pharma USD $695 More Info
    Trends and Innovations in Drug Pricing
    IntroductionFirstWord’s Trends and Innovations in Drug Pricing report dissects international trends ...
    01 Jan 2015 by FirstWord Pharma USD $695 More Info
    Orphan Drug Market Access: Payer Insights on the Present and Future
    IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
    14 Oct 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: With drug developers on the brink of Phase III for NASH, how large is the actual market opportunity?
    Scope While no drugs are approved for non-alcoholic steatohepatitis (NASH), at least eight agents ha...
    04 Aug 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up?
    ScopeSales of Biogen Idec’s multiple sclerosis therapy Tecfidera may continue to exceed initial expe...
    01 Nov 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Drug Delivery - Innovations, trends, and their impact on pharma | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data